NL-OMON46178撤回3 期
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants with Genetically Diagnosed and Pre-Symptomatic Spinal Muscular Atrophy with Multiple Copies of SMN2 - SPR1NT
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- A
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 11（—）
入选标准
- •All patients
- •* Age *6 Weeks (*42 days) at time of dose
- •* Ability to tolerate thin liquids as demonstrated through a formal bedside swallowing test
- •* Compound muscle action potential (CMAP) *2 mV at Baseline; centralized review of CMAP data will be conducted
- •* Gestational age of 35 to 42 weeks
- •* Up-to-date on childhood vaccinations. Seasonal vaccinations that include palivizumab prophylaxis (also known as Synagis) to prevent respiratory syncytial virus (RSV) infections are also recommended in accordance with the guidance of local health authorities.
- •* Able and willing to follow the Consensus Statement for Standard of Care in Spinal Muscular Atrophy.
- •* Parent(s)/legal guardian(s) willing and able to complete the informed consent process and comply with study procedures and visit schedule
- •* Genetic diagnosis as described below, obtained from an acceptable newborn or pre-natal screening test method
- •Patients with 2 copies of SMN2 (n *15)
- •* Patients with pre-symptomatic SMA Type 1 as determined by the following features:
- •* 2 copies of SMN2
- •Patients with 3 copies of SMN2 (n *12)
- •* Patients with pre-symptomatic SMA Type 2 as determined by the following features:
- •* 3 copies of SMN2
排除标准
- •* Weight at screening visit <2 kg
- •* Hypoxemia (oxygen saturation <96% awake or asleep without any supplemental oxygen or respiratory support) at the screening visit or for altitudes >1000 m, oxygen saturation <92% awake or asleep without any supplemental oxygen or respiratory support at the screening visit
- •* Any clinical signs or symptoms at screening or immediately prior to dosing that are, in the opinion of the Investigator, strongly suggestive of SMA (e.g., tongue fasciculation, hypotonia, areflexia)
- •* Tracheostomy or current prophylactic use or requirement of non invasive ventilatory support at any time and for any duration prior to screening or during the screening period
- •* Patients with signs of aspiration/inability to tolerate non thickened liquids based on a formal swallowing test performed as part of screening or patients receiving any non-oral feeding method
- •* Clinically significant abnormalities in hematology or clinical chemistry parameters as determined by the investigator or medical monitor
- •* Treatment with an investigational or commercial product, including nusinersen, given for the treatment of SMA. This includes any history of gene therapy, prior antisense oligonucleotide treatment, or cell transplantation.
- •* Patients whose weight-for-age is below the third percentile based on World Health Organization (WHO) Child Growth Standards [33]
- •* Biological mother with active viral infection as determined by screening laboratory samples (includes human immunodeficiency virus [HIV] or positive serology for hepatitis B or C)
- •* Biological mothers with clinical suspicion of Zika virus that meet Centers for Disease Control and Prevention (CDC) Zika virus epidemiological criteria including history of residence in or travel to a geographic region with active Zika transmission at the time of travel will be tested for Zika virus RNA; positive results warrant confirmed negative Zika virus ribonucleic acid (RNA) testing in the patient prior to enrollment
- •* Serious non respiratory tract illness requiring systemic treatment and/or hospitalization within 2 Weeks prior to screening
- •* Upper or lower respiratory infection requiring medical attention, medical intervention, or increase in supportive care of any manner within 4 Weeks prior to dosing
- •* Severe non pulmonary/respiratory tract infection (e.g., pyelonephritis, or meningitis) within 4 Weeks before administration of gene replacement therapy or concomitant illness that, in the opinion of the Investigator or Sponsor medical monitor, creates unnecessary risks for gene replacement therapy such as:
- •* Major renal or hepatic impairment
- •* Known seizure disorder
- •* Diabetes mellitus
- •* Idiopathic hypocalciuria
- •* Symptomatic cardiomyopathy
- •* Known allergy or hypersensitivity to prednisolone or other glucocorticosteroids or their excipients
- •* Previous, planned or expected major surgical procedure including scoliosis repair surgery/procedure during the study assessment period
- •* Concomitant use of any of the following: drugs for treatment of myopathy or neuropathy, agents used to treat diabetes mellitus, or ongoing immunosuppressive therapy, plasmapheresis, immunomodulators such as adalimumab, immunosuppressive therapy within 4 Weeks prior to gene replacement therapy (e.g., corticosteroids, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, IV immunoglobulin, rituximab)
- •* Anti AAV9 antibody titer >1:50 as deter
研究者
相似试验
进行中（未招募）
1 期
Single dose gene replacement therapy clinical trial for infants with genetically diagnosed and pre-symptomatic Spinal Muscular AtrophySpinal Muscular AtrophyEUCTR2017-004087-35-BEAveXis, Inc.29
进行中（未招募）
1 期
Single dose gene replacement therapy clinical trial for infants with genetically diagnosed and pre-symptomatic Spinal Muscular AtrophySpinal Muscular AtrophyEUCTR2017-004087-35-DEAveXis, Inc.27
进行中（未招募）
1 期
Single dose gene replacement therapy clinical trial for infants with genetically diagnosed and pre-symptomatic Spinal Muscular AtrophySpinal Muscular AtrophyEUCTR2017-004087-35-NLAveXis, Inc.30
进行中（未招募）
1 期
Single dose gene replacement therapy clinical trial for infants with genetically diagnosed and pre-symptomatic Spinal Muscular AtrophySpinal Muscular AtrophyEUCTR2017-004087-35-GBovartis Gene Therapies, Inc.29
进行中（未招募）
1 期
A trial to learn about a study drug (STAR-0215) in adults with hereditary angioedemaHereditary angioedema (HAE)Circulatory SystemISRCTN99457796Astria Therapeutics, Inc29